Commercial
Uncorking the compliance bottlenecks in digital
The sudden demand for digital content this year has created serious compliance bottlenecks that pharma is racing to overcome with new processes and technology
More Articles
Clinical
Maimah Karmo: Surviving, fighting, winning
The Tigerlily Foundation President and Founder is more hopeful than ever that she can help pharma give Black women the representation they deserve in trials and beyond
Medical
COVID-19: A data challenge and a catalyst for new insights
The healthcare ecosystem has demonstrated its ability to share data to uncover new insights this year but there is more to be done, says Nigel Hughes, scientific director at Epidemiology, Janssen R&D
Patients and Medical
Building a health equity culture
Health inequities, often a legacy of racism, lie heavy on the healthcare sector in the US and beyond. Fixing the problem will require long-term effort on multiple fronts
Commercial
Creating a holistic customer experience
Finding solutions to unmet customer needs means harnessing the combined power of medical and marketing skills – and creating a culture to match
Multichannel
Reimagining the life sciences beyond COVID-19
A new report from Reuters Events Pharma and EY reveals the impacts on the life sciences sector and analyses the road ahead
Clinical
Automation is key in cell and gene therapy manufacturing
Although the list of cell and gene therapies is growing, prices remain high. Now developers are working on a road map to streamline production and drop costs
Multichannel
How sustainable is remote health at scale?
Remote health has proved its worth to the entire healthcare sector but sustaining and scaling it requires work from every stakeholder
Patients and Medical
Digital companions: helping improve patient treatment journeys
The virtual health explosion isn't going away. This just at the start of an era of digital enhancement
Patients and Medical
Racially diverse clinical trials: A new patient-led legacy takes root
Attempts to make trials more diverse aren’t working. To overcome far-reaching inequality and deep distrust, pharma must be educated by, as well as educate, under-served communities